Physician profile
Abdullah Al-Abcha
NPI 1669958724
$838.87
in general payments reported to CMS, 2019-2025
10 companies · $526 in 2025
The $526 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $91.29 · 2021: $28.37 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.41 |
| Education | $182.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $302.18 | 2025 | |
| Medtronic, INC. | $182.75 | 2025 | Resolute Onyx |
| Astrazeneca Pharmaceuticals LP | $131.59 | 2019 | |
| Boston Scientific Corporation | $91.29 | 2020 | |
| Edwards Lifesciences Corporation | $39.60 | 2021-2025 | Pascal |
| Glaxosmithkline, LLC. | $32.34 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.40 | 2025 | Opsynvi |
| Shire North American Group INC | $15.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Al-Abcha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.